Companies To Watch
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
Companies To Watch: Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is pitting new and potent antivirals versus COVID, Ebola, and other coronaviruses.
Companies To Watch: Osivax
Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.
Companies To Watch: CalciMedica
“In a sense, the Covid association was a golden opportunity for our drug,” says Rachel Leheny, CEO of CalciMedica, a pharma focused on anti-inflammatories for pancreatitis that has now shifted to treatments for Covid-19 pneumonia.
Companies To Watch: Cidara Therapeutics
Cidara Therapeutics is training its novel treatment and preventative for flu and other viral infections on Covid-19.
Companies To Watch: Equillium
Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.
Companies To Watch: Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.
Companies To Watch: argenx
Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.
Companies To Watch: Neurana
This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.
Companies To Watch: Adaptive Phage Therapeutics
Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.
Companies To Watch: Imago BioSciences
In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.
Companies To Watch: Scynexis
Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.
Companies To Watch: Obsidian Therapeutics
Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.
Companies To Watch: eXIthera
This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.
Companies To Watch: Leading Biosciences
Leading Biosciences is applying the science of digestive proteases to treating or preventing multiple diseases and conditions, starting with delayed return of post-surgical bowel function (ileus) and adhesion with its lead product candidate, coded LB1148.
BEYOND THE PRINTED PAGE
9 Biopharma CEOs On COVID-19 Induced Trend Opportunities
This year’s CEO outlook article in Life Science Leader’s annual outlook issue, published in December, has 15 CEOs taking part! Some members of this year’s CEO class were posed a question around what COVID-19 induced trends they envisioned sticking around well beyond the end of this pandemic.
What COVID-19 Causations Will Continue In 2021 And Beyond?
Unprecedented. That’s the word used ad nauseam to describe much of what we experienced in 2020. And while many of these moves were unprecedented at the time, now that they’ve been done, they now serve as a precedent. This makes you wonder just how many COVID-19 causations will continue into 2021 and beyond?
Henri Termeer – A Much Missed Mentor
Chief Editor Rob Wright talks about the last time he spoke with Henri Termeer, who was a mentor to Paula Ragan, Ph.D., cofounder and CEO of X4 Pharmaceuticals (subject of the November 2020 cover feature in Life Science Leader).
LIFE SCIENCE LEADER BLOGS
What Would You Do?
A call with a young reader reveals a biopharmaceutical industry mentorship opportunity beyond science.
What Does Travel Look Like For You In 2021?
With the annual J.P. Morgan Healthcare conference going virtual in January of 2021, Rob Wright asks readers about their business travel plans for next year, and includes anonymized thoughts on posed questions from two Life Science Leader editorial advisory board members.